Prescription medicine
Pancrelipase amylase and pancrelipase lipase and pancrelipase protease Brand names: Creon, Zenpep, Pancreaze, Pertzye, Viokace
Pancrelipase amylase and pancrelipase lipase and pancrelipase protease (Creon) is a prescription medicine. No generic is listed; pharmacies paid $4.21 per Creon DR 12,000 unit capsule in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the pancrelipase amylase and pancrelipase lipase and pancrelipase protease FDA label on DailyMed (effective February 28, 2024); every pancrelipase amylase and pancrelipase lipase and pancrelipase protease label on DailyMed.
Highlights of the record
FDA label of February 28, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageCREON ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients.
Forms and strengths
Delayed-release capsule; capsule (delayed release pellets); tablet.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 4 of which 0 under generic applications, 4 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $4.21 per capsule Creon DR 12,000 unit capsule
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 3 since 2014 0 Class I among all firms' recalls; latest June 23, 2023
- FAERS reports
- 44,543 through July 30, 2026
What is pancrelipase amylase and pancrelipase lipase and pancrelipase protease used for?
From the label: indications and usageCREON ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. CREON is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients.
Source: FDA drug label (Creon), AbbVie Inc., effective February 28, 2024 (SPL set 073201aa-556d-4a70-918e-84e9616fd88d), via openFDA; the full label on DailyMed
What does the patient leaflet for pancrelipase amylase and pancrelipase lipase and pancrelipase protease say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about CREON?CREON may increase your chance of having a rare bowel disorder called fibrosing colonopathy especially if taken at a high dose for a long time in children with cystic fibrosis. This condition is serious and may require surgery. The risk of having this condition may be reduced by following the dosing instructions that your healthcare provider gave you. Call your healthcare provider right away if you have any unusual or severe: stomach area (abdominal) pain bloating trouble passing stool (having bowel movements) nausea, vomiting, or diarrhea Take CREON exactly as prescribed. Do not take more or less CREON than directed by your healthcare provider.
From the patient leaflet: How should I store CREON?Store CREON at room temperature between 59°F to 77°F (15°C to 25°C). Avoid heat. You may store CREON at a temperature between 77°F to 104°F (25°C to 40°C) for up to 30 days. Throw away any CREON stored at these temperatures for more than 30 days. Keep CREON in a dry place and in the original container. After opening the bottle, keep it closed tightly between uses to protect from moisture. If there is a moisture-absorbing packet (desiccant) in the bottle, keep it in the bottle. Do not eat it or throw it away. Keep CREON and all medicines out of the reach of children.
Source: FDA drug label (Creon), AbbVie Inc., effective February 28, 2024 (SPL set 073201aa-556d-4a70-918e-84e9616fd88d), via openFDA; the full label on DailyMed
Is there a generic for pancrelipase amylase and pancrelipase lipase and pancrelipase protease (Creon)?
No generic pancrelipase amylase and pancrelipase lipase and pancrelipase protease is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for pancrelipase amylase and pancrelipase lipase and pancrelipase protease (Creon)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $4.21 per Creon DR 12,000 unit capsule, up 2% from $4.11 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Creon DR 6,000 unit capsule (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Creon DR 12,000 unit capsule | Brand | $4.21 per capsule | $126.22 | +2% |
| Creon DR 24,000 unit capsule | Brand | $8.34 per capsule | $250.25 | +2% |
| Creon DR 3,000 unit capsule | Brand | $1.78 per capsule | $53.28 | +2% |
| Creon DR 36,000 unit capsule | Brand | $12.67 per capsule | $380.13 | +2% |
| Creon DR 6,000 unit capsule | Brand | $2.10 per capsule | $63.15 | +2% |
| Pertzye DR 16,000 unit capsule | Brand | $5.33 per capsule | $159.86 | +2% |
| Pertzye DR 24,000 unit capsule | Brand | $8.04 per capsule | $241.16 | +3% |
| Pertzye DR 8,000 unit capsule | Brand | $2.66 per capsule | $79.94 | +3% |
| Viokace 10,440-39,150 unit tablet | Brand | $4.15 per tablet | $124.52 | +3% |
| Viokace 20,880-78,300 units tablet | Brand | $8.21 per tablet | $246.38 | +3% |
| Zenpep DR 10,000 unit capsule | Brand | $4.18 per capsule | $125.52 | +4% |
| Zenpep DR 15,000 unit capsule | Brand | $6.04 per capsule | $181.33 | +4% |
| Zenpep DR 20,000 unit capsule | Brand | $8.20 per capsule | $246.01 | +4% |
| Zenpep DR 25,000 unit capsule | Brand | $10.15 per capsule | $304.39 | +4% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has pancrelipase amylase and pancrelipase lipase and pancrelipase protease been recalled?
The FDA's Enforcement Report lists 3 recalls naming pancrelipase amylase and pancrelipase lipase and pancrelipase protease since 2014: 0 Class I (the most serious), 2 Class II, 1 Class III; 1 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| June 23, 2023 | Class III | Vivus, Inc. | Failed Stability Specifications |
| March 15, 2021 | Class II | Cardinal Health Inc. | CGMP Deviations: Intermittent exposure to temperature excursion during storage. |
| September 15, 2014 | Class II | AbbVie Inc | Presence of Foreign Tablets/Capsules; Presence of co-mingled LipaCreon 13000. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What do FAERS reports show for pancrelipase amylase and pancrelipase lipase and pancrelipase protease?
The FDA Adverse Event Reporting System holds 44,543 reports that list pancrelipase amylase and pancrelipase lipase and pancrelipase protease among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 4,263 are coded as a death and 17,057 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Pancrelipase amylase and pancrelipase lipase and pancrelipase protease side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other